🟢 MetaVia is trading 6.52% up in pre-market with no identified catalyst

MetaVia is trading at $1.47, up 6.52% in pre-market, with no identified company-specific catalyst.

• No new company announcement explaining the October 26 pre-market move was identified; MetaVia’s investor-relations page lists its October 13 chief medical officer appointment as its latest release.
• Available news coverage shows no newer company-specific catalyst. Supplied major-index moves are mixed and below 0.5%; the cause of the early gain remains unclear, and the October 13 appointment is prior news, not a confirmed explanation.